ASX ANNOUNCEMENT **ASX:NSB**

NeuroScientific and Lions Eye Institute Research Collaboration

Perth, Australia; September 20, 2018: NeuroScientific Biopharmaceuticals Limited (**ASX:NSB**) and the Lions Eye Institute (LEI) have entered into a research agreement to develop NeuroScientific's lead drug candidate, EmtinB, as a treatment for eye diseases that affect the optic nerve. LEI is one of Australia's leading ophthalmic research institutes and is globally recognised as a centre for first-class scientific research into eye diseases.

The research program will be led by Professor Dao-Yi Yu, Head of the Physiology and Pharmacology Research Group at LEI. Supported by a core research team of multidiscipline experts from research scientists to clinical specialists, Professor Yu recently led the development of a treatment for glaucoma that was acquired by global pharmaceutical company Allergan.

The research collaboration will fully explore EmtinB's potential to treat conditions of the eye that result in degeneration of the optic nerve. The optic nerve is responsible for transmitting visual information from the eye to the brain. Damage to the optic nerve results in various degrees of irreversible vision loss. EmtinB can promote the survival and regeneration of nerve cells, which has been validated in models of neurodegenerative disease, and has the potential to promote the same effect in optic nerve cells. Additionally, a previous study involving the parent compound of EmtinB resulted in the regeneration of the optic nerve in rats following complete surgical transection of their optic nerve.

"NeuroScientific is pleased to be entering into a collaborative partnership with the Lions Eye Institute and Professor Yu's esteemed team," said Mr Matt Liddelow, Chief Executive Officer and Managing Director of NeuroScientific. "I look forward to working with Professor Yu's team and further exploring the potential for development of EmtinB as a first-in-class treatment for conditions that affect the optic nerve. This research should also support the development of EmtinB in other treatment indications beyond neurodegenerative diseases, in turn maximising the commercial return for shareholders across multiple market opportunities."

Professor Yu said, "I am happy that my team has the opportunity to work with NeuroScientific on this exciting project. Diseases involving optic nerve damage are the second most common cause of blindness in our community, so the opportunity to work with a new compound that might have protective effects on the optic nerve is exciting."

NeuroScientific will make a statement on the research outcomes upon completion of the study.

About Neuroscientific Biopharmaceuticals Limited

NeuroScientific Biopharmaceuticals (ASX:NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have

demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

About the Lions Eye Institute

The Lions Eye Institute (LEI) is a not-for-profit medical research institute that combines world class scientific research into the prevention of blindness with the highest level of eye care delivery. It incorporates one of Australia's largest ophthalmic practices and Clinical Trials units.

The LEI teams investigate all major causes of blindness including cataracts, diabetes related eye disease, glaucoma, retinal degenerations, corneal, and immune-based diseases. LEI scientists use a range of methodologies and technologies to develop treatments for blinding diseases. The LEI has diverse, multi-faceted national and international institutional partnerships including but not limited to the American Juvenile Diabetes Foundation, Fudan University (Shanghai), Swedish University of Agricultural Science, University of Missouri and the National Eye Institute (USA).

Research carried out by Institute teams led to the first retinal vein bypass treatment of blockages, and the development of the first transgenic mouse model for Age-Related Macular Degeneration, the leading cause of blindness for people over 55. LEI developed the first artificial cornea as well as an implantable transscleral microsurgical device that was approved for use in the USA by the FDA in 2016. The LEI is acknowledged as a core academic centre involved in clinical trials of new pharmaceutical therapies and surgical procedures before regulatory approval.

Contacts

Mr Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Thomas Spencer
CFO & Company Secretary
ir@neuroscientific.com
+61 491 108 250